Zobrazeno 1 - 10
of 170
pro vyhledávání: ''
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.
Publikováno v:
Anticancer Research. 41:1593-1598
Background/aim We previously showed that an elevated postoperative serum C-reactive protein (CRP) level has a negative impact on long-term survival outcomes, regardless of the occurrence of infectious complications in colorectal cancer. However, the
Autor:
Jan C. Peeken, Benjamin Schlossmacher, Florian Lenze, Ulrich Lenze, Ruediger von Eisenhart-Rothe, Stephanie E. Combs, Alexandra S. Gersing, Rainer Burgkart, Heinrich M L Muehlhofer, Carolin Knebel
Publikováno v:
Anticancer Research. 41:359-368
BACKGROUND/AIM Surgical resection for soft tissue sarcomas (STSs) is the gold standard for a curative oncologic therapy in combination with neoadjuvant or adjuvant radiation therapy (NRT/ART). The aim of this study was to determine prognostic factors
Publikováno v:
Anticancer Research. 41:187-195
Background Amplification of chromosome 8q with locus 8q24 is the most common copy number aberration, and is associated with tumour progression and chemoresistance. Materials and methods The study used paired samples of biopsy and surgical material fr
Publikováno v:
Anticancer Research. 41:101-111
Background/aim The expression of tumor-associated programmed death-ligand 1 (PD-L1) predicts clinical responses to PD-1-directed immunotherapy. The expression levels of PD-L2, another PD-1 ligand, and its relationship with responses to PD-1-targeting
Autor:
Paloma Lluch, Guadalupe Herrera, Pascual Medina, Joan Tosca, Salvador Lluch, Javier Navarrete-Navarro, Ana Sanahuja, Sherly Hernandez, Gloria Segarra, Laia Navarro
Publikováno v:
Anticancer Research. 40:6853-6861
Background/aim In chronic liver disease, various immune cell subsets exert pro or anti-tumour effects by releasing reactive oxygen and nitrogen species (ROS, RNS). Here, we evaluated the oxidative and nitrosative pattern in peripheral blood leukocyte
Autor:
Toshifumi Takahashi, Makiko Ueda, Shu Soeda, Takafumi Watanabe, Yuta Endo, Tetsu Sato, Hidekazu Nishigori, Norihito Kamo, Shigenori Furukawa, Shinji Nomura, Chikako Okabe, Keiya Fujimori, Kojima Manabu
Publikováno v:
Anticancer Research. 40:5263-5270
Background Treatment for platinum-resistant ovarian cancer is difficult and challenging because available chemotherapeutic agents only offer short survival improvements. The efficacy of re-treatment with platinum-based agents including nedaplatin for
Autor:
Masatoshi Matsuo, Tatsuro Jo, Kuniko Abe, Jun Taguchi, Hiroo Tominaga, Ritsuko Kubota-Koketsu, Yohei Kaneko, Shizuka Hayashi, Kazuto Shigematsu, Takahiro Sakai, Kaori Matsuzaka, Haruna Shioya
Publikováno v:
Anticancer Research. 40:5237-5243
Background/aim Adult T-cell leukemia/lymphoma (ATLL) is a relatively refractory CD4-positive peripheral T-cell lymphoma. VCAP-AMP-VECP (mLSG15) is one of the standard chemotherapeutic regimens for patients with aggressive ATLL. Mogamulizumab (moga),
Autor:
Kiyoaki Tsukahara, Chihiro Fushimi, Hiroki Sato, Hideaki Takahashi, Takahito Kondo, Yuichiro Tada, Kouki Miura, Tatsuo Masubuchi, Go Omura, Takashi Matsuki, Kenji Hanyu, Takuro Okada, Isaku Okamoto, Taku Yamashita
Publikováno v:
Anticancer Research. 40:5277-5283
Background/aim The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) has remained challenging. The effect of salvage chemotherapy (SCT) after nivolumab has been identified recently in other cancer ty
Autor:
Kazuhiko Shien, Yuta Takahashi, Shinichi Toyooka, Masaomi Yamane, Hiromasa Yamamoto, Susumu Kanazawa, Junichi Soh, Katsuyuki Kiura, Hiroyuki Yanai
Publikováno v:
Anticancer Research. 40:4419-4423
Background/aim The histological features of lymph nodes (LNs) treated by chemoradiotherapy (CRT) in non-small cell lung cancer (NSCLC) have not been well studied. The purpose of this study was to evaluate the histological findings of LNs affected by